CD19 and precursor B-cell acute lymphoblastic leukemia: Thus, decreased CD19 and CD22 surface expression due to low IKAROS levels reduces the efficacy of CD19- and CD22-targeted therapies and B-ALL cell killing, demonstrating that IKAROSlow cells have a survival advantage in the face of these therapies (Fig. 5).